Catalyst
Slingshot members are tracking this event:
Galena Biopharma Presents GALE-401 Combined Safety Data at the European Hematology Association 21st Congress
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
GALE |
|
|
Additional Information
In the healthy volunteer studies, single and multiple doses of GALE-401 were safe and well tolerated and there were no clinically relevant changes in vital signs, electrocardiograms, and safety laboratory parameters other than a reduction in platelet counts. The most frequent treatment emergent adverse events reported included headache, pain in extremities or back, palpitations and gastrointestinal disturbances. In the Phase 2 MPN trial, patients treated with GALE-401 exhibited fewer of the more common adverse events associated with anagrelide IR (cardiac; general; gastrointestinal; respiratory, thoracic, and mediastinal; skin and subcutaneous tissue; nervous system). Some of the less common AEs of anagrelide IR were comparatively more frequent for GALE-401 (vascular; hepatobiliary; blood and lymphatic).
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 13, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Gale-401, Thrombocythemia, Anagrelide Ir